Trinity College Dublin Develops Needle-Free Nasal Vaccine That Blocks Whooping Cough Transmission
Key Insights
Researchers at Trinity College Dublin have developed a needle-free nasal vaccine using antibiotic-inactivated Bordetella pertussis (search) (AIBP) that prevents both whooping cough (search) infection and bacterial transmission.
The vaccine outperformed current injected vaccines in preclinical mouse studies by activating T-cells (search) and providing mucosal immunity directly at respiratory infection sites.
This breakthrough addresses a critical gap in whooping cough (search) prevention, as current vaccines protect against severe disease but fail to prevent bacterial colonization and community spread.
Researchers at Trinity College Dublin have developed a groundbreaking needle-free nasal vaccine that not only prevents whooping cough (search) but also blocks bacterial transmission—a critical advancement that could transform respiratory disease prevention. The findings, published in Nature Microbiology, demonstrate that the antibiotic-inactivated Bordetella pertussis (search) (AIBP) vaccine outperformed current injected vaccines in preclinical studies.
Addressing Critical Vaccine Limitations
Despite high vaccination rates globally, whooping cough (search) continues to cause 160,700 deaths annually in children younger than five. The persistent circulation of pertussis (search) stems from a fundamental limitation of current vaccines: while they protect individuals from severe disease, they fail to prevent bacterial colonization in the nose and throat, allowing continued community transmission.
"Current whooping cough (search) vaccines, while life-saving, have key limitations," the research team noted. "They protect infants from severe illness but fail to prevent bacterial colonisation in the nose and throat—allowing the illness to spread within communities."
The new AIBP vaccine (search) addresses this gap by delivering immunity directly at the infection site through nasal administration, providing what researchers describe as "stronger protection" with the potential to "interrupt community transmission."
Breakthrough in Mucosal Immunity
The vaccine works by stimulating mucosal immunity—the body's first line of defense in the airways. Professor Kingston Mills of Trinity's School of Biochemistry and Immunology explained the approach: "We've applied our understanding of protective immune pathways to engineer a fundamentally different kind of vaccine. By stimulating immunity where infections begin, at the respiratory mucosa (search), we can offer stronger protection and potentially interrupt community transmission."
In preclinical studies conducted in mice, the intranasal AIBP vaccine (search) demonstrated superior performance compared to standard injected vaccines. The vaccine prevented bacterial colonization in both the lungs and nasal cavity by inducing a T-cell-driven mucosal immune response without triggering harmful systemic inflammation.
Technical Innovation and Methodology
The AIBP vaccine (search) uses an innovative approach where Bordetella pertussis bacteria are killed using antibiotics to create a whole-cell vaccine suitable for respiratory tract administration. By administering the vaccine through the nose, researchers found it activated T-cells (search) that help the body fight germs in the lungs and upper respiratory tract.
This T-cell activation represents a significant advancement over current vaccines, which primarily rely on antibody responses that may not effectively prevent initial bacterial colonization at mucosal surfaces.
Broader Platform Potential
The research team, led by Kingston Mills and Davoud Jazayeri, suggests the technology could serve as a next-generation platform adaptable for other respiratory pathogens. The findings indicate potential applications for vaccines against Staphylococcus aureus, Streptococcus pneumoniae, Mycoplasma pneumoniae, and Mycobacterium tuberculosis (search)—all of which remain major global health and economic burdens.
Current Disease Burden and Vaccine Challenges
The urgency of this development is underscored by recent epidemiological data. More than 500 cases of whooping cough (search) were reported in the UK between January and June of this year, including eight cases in babies under three months old, according to UKHSA data.
Vaccine uptake has declined significantly, with rates among children in England now at their lowest level in 15 years. Almost one in five children starting primary school in England were not fully protected against diseases including whooping cough (search), polio, tetanus, and diphtheria. Vaccination rates among pregnant women have also declined from a peak of 76% in 2016 to 59% by March of the previous year, though recent improvements have brought uptake to 73%.
Industry Context and Future Development
The project, initially funded through a Science Foundation Ireland Frontiers for the Future Award, is now advancing under the ARC Hub for Therapeutics—a €32 million national translational research initiative co-funded by the Government of Ireland and the European Union through the European Regional Development Fund.
The findings build on renewed industry focus on vaccines that act where infections take hold in the airways. The COVID-19 (search) pandemic highlighted that while injectable vaccines can prevent severe illness, they are less effective at stopping viral spread, prompting companies to explore nasal formulations designed to elicit mucosal immunity.
While companies like AstraZeneca, Bharat Biotech, and CanSino Biologics (search) have pursued similar nasal vaccine strategies for COVID-19 (search) with varying degrees of success, Trinity's AIBP results demonstrate the potential for achieving both disease prevention and transmission control—a combination that could redefine respiratory vaccine development.
The research team emphasizes that more studies are needed before the vaccine can be tested in humans, but the preclinical results represent a significant step toward addressing the dual challenge of individual protection and community transmission prevention in respiratory infectious diseases.